Javier Martin Broto Date of document: 20/03/2020 v 1.4.0 80568224a509ac22d7ad18cde2e9f428 - Instituto de Biomedicina de Sevilla
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Javier Martin Broto
Generated from: Editor CVN de FECYT
Date of document: 20/03/2020
v 1.4.0
80568224a509ac22d7ad18cde2e9f428
This electronic file (PDF) has embedded CVN technology (CVN-XML). The CVN technology of this file allows you to export and import curricular data from and
to any compatible data base. List of adapted databases available at: http://cvn.fecyt.es/80568224a509ac22d7ad18cde2e9f428
Summary of CV
This section describes briefly a summary of your career in science, academic and research; the
main scientific and technological achievements and goals in your line of research in the medium
-and long- term. It also includes other important aspects or peculiarities.
Dr Javier Martin Broto is a medical oncologist at the Universitary Hospital Virgen del Rocio,
and he is leading, at the Instituto de Biomedicina de Sevilla (IBIS), Seville (Spain) the lab team
of the Advanced Therapies and Biomarkers in Sarcomas (TERABIS). He was born 53 years
ago in Huesca province, Spain. He studied Medicine between 1982 and 1988 in the School
of Medicine of Zaragoza, obtaining the official title of Specialist in Medical Oncology in Son
Dureta Hospital, Palma de Mallorca, in 1994 after successfully passing a national exam. From
1994 to 2014 devoted to sarcoma care in this Hospital that became part of Center of Reference
for Sarcoma.
From September 2014 he moved to University Hospital of Virgen del Rocio in Sevilla to
coordinate the multidisciplinary sarcoma team and to apply for a selective number of centers
of reference in Sarcoma Care in our Country. Finally our Center was accredited as National
Health System Reference Center for Sarcoma Care (along with other 4 Hospitals). Likewise
our Center is one accredited within ERN (European Network for Rare Diseases) as European
Center of Reference in Sarcoma from 2017.
Founder Member of The Spanish Group for Research on Sarcomas (GEIS) in 1994 and
currently vice-chairman of this group from 2019 (He was GEIS Chairman from 2010 to 2018).
He obtained PhD degree on Molecular Biology in 2010 focusing on molecular prognostic
biomarkers in GIST. Member of American Society of Clinical Oncology (ASCO), of European
Society of Medical Oncology (ESMO) where is chair of sarcoma track, of Connective Tissue
Oncology Society (CTOS), of Sociedad Española de Oncología Médica (SEOM). ESMO
Faculty member in Sarcomas from 2010 and he was member of board directors of CTOS
from 2014 to 2018. He is member of Steering committee of EURACAN network. Currently he
combines clinical sarcoma assistance with translational research, leading a basic research
team in the lab. Additionally, he’s running and designing several trials on sarcoma 2 patients,
some of them as coordinator at national and international level. He is the author/coauthor of
more than 100 manuscripts in sarcoma including first author in journals as Journal Clinical
Oncology, Lancet Oncology, JAMA Oncology, Annals of Oncology, and Molecular Cancer
Therapeutics among others. He is leading the consortium SELNET through Horizon 2020
grant; this network involves LatinAmerican and European countries.
280568224a509ac22d7ad18cde2e9f428
General quality indicators of scientific research
This section describes briefly the main quality indicators of scientific production (periods of
research activity, experience in supervising doctoral theses, total citations, articles in journals of
the first quartile, H index...). It also includes other important aspects or peculiarities.
Citation Index Total Since 2012
Citations 6393 3993
h-index 40 31
i10-index 117 78
380568224a509ac22d7ad18cde2e9f428
Javier Martin Broto
Surname(s): Martin Broto
Name: Javier
DNI: 18018895M
ORCID: 0000-0001-7350-6916
ResearcherID: AAI-2313-2019
Date of birth: 23/06/1964
Gender: Male
Land line phone: 955923113 - 302113
Email: jmartin@mustbesevilla.org
Current professional situation
Employing entity: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
Professional category: Responsible Investigator (PI)
Start date: 2015
Employing entity: INSTITUTO DE BIOMEDICINA DE SEVILLA
Professional category: Adjunto Oncología Medica Nº Colegiado 0704499
Start date: 01/09/2014
Type of contract: Permanent employment Dedication regime: Full time
contract
Primary (UNESCO code): 240000 - Life Science
Secondary (UNESCO code): 240000 - Life Science
Tertiary (UNESCO code): 320000 - Medical Science
Identify key words: Natural sciences and health sciences
Previous positions and activities
Employing entity Professional category Start date
1 Grupo Español de investigación en Presidente 2010
Sarcomas
2 Hospital Universitario Son Espases Oncología Médica 01/11/2010
3 Hospital Universitario Son Dureta Oncología Médica 01/01/1994
1 Employing entity: Grupo Español de investigación en Sarcomas
Professional category: Presidente
Start-End date: 2010 - 2018 Duration: 8 years
2 Employing entity: Hospital Universitario Son Type of entity: Hospital
Espases
Professional category: Oncología Médica
Start-End date: 01/11/2010 - 31/08/2014
480568224a509ac22d7ad18cde2e9f428
3 Employing entity: Hospital Universitario Son Type of entity: Healthcare Institutions
Dureta
Professional category: Oncología Médica
Start-End date: 01/01/1994 - 31/10/2010
580568224a509ac22d7ad18cde2e9f428
Education
University education
1st and 2nd cycle studies and pre-Bologna degrees
1 Name of qualification: Residency in Medical Oncology
Degree awarding entity: Hospital Universitario Son Type of entity: Healthcare Institutions
Dureta
Date of qualification: 31/07/1994
2 Name of qualification: Degree in Medicine
Degree awarding entity: Universidad de Zaragoza
Date of qualification: 30/06/1988
Doctorates
Doctorate programme: PhD in Health Sciences
Degree awarding entity: Universidad de las Islas Type of entity: University
Baleares
Date of degree: 14/07/2009
Language skills
Language Listening skills Reading skills Spoken interaction Speaking skills Writing skills
French B1 A1 A1 A1
Catalan C1 C1 C1 C1
Spanish C1 C1 C1 C1
English C1 C1 C1 C1
Teaching experience
General teaching experience
1 Name of the course: ‘Curso Avanzado de Sarcoma para residentes’
Start date: 2010 End date: 2015
Entity: GEIS
2 Name of the course: Oncología Médica. Tutor de residentes, Profesional docente
University degree: Oncología Médica
Start date: 1995 End date: 2014
Entity: Hospital Universitario Son Dureta
680568224a509ac22d7ad18cde2e9f428
Faculty, institute or centre: 527 horas
3 Name of the course: Biología del cáncer. Sarcomas.
University degree: Máster de la Universitat de les Illes Balears
Start date: 2012 End date: 2013
4 Name of the course: Máster de la Universidad de Las Islas Baleares en Biología del cáncer. Capítulos sobre
sarcomas. Mayo/2013
University degree: Máster de la Universidad de Las Islas Baleares en Biología del cáncer
Start date: 2012 End date: 2013
Entity: Universidad de Las Islas Baleares
Faculty, institute or centre: Profesosr 14 creditos
5 Name of the course: “GIST: Diagnosis, staging and therapy”
Entity: ESMO-ESO Course on Medical Oncology for Medical Students
6 Name of the course: Terapias en sarcoma: sarcoma partes blandas; GI y óseo
Entity: Curso de Patología Molecular y terapia en sarcoma del Centro de Estudios Biosanitarios
Experience supervising doctoral thesis and/or final year projects
1 Project title: Analisis de FasR/FasL como factor pronostico/predictivo en GIST localizado. Revision cientifica del
proyecto de investigacion
Entity: Universidad de Sevilla Type of entity: University
Student: Omar Saavedra Santa Gadea
Date of reading: 2015
2 Project title: Analisis de FasR/FasL como factor pronostico/predictivo en GIST. Enfermedad localmente avanzada
y metastasica.Revision cientifica del proyecto de investigacion
Entity: Universidad de Sevilla Type of entity: University
Student: Natalia Palazon Carrio
Date of reading: 2015
3 Project title: Análisis exploratorio de factores genéticos predictivos de respuesta al tratamiento en sarcoma de
Ewing metastático
Entity: Universidad de Sevilla Type of entity: University
Student: Alejandro GONZALEZ Forastero
4 Project title: Análisis exploratorios de factores moleculares pronósticos en tumores desmoides
Entity: Universidad de Sevilla Type of entity: University
Student: Johanna Benedetti Pedroza
780568224a509ac22d7ad18cde2e9f428
Student tutorials
Name of the programme: Practicas externas Fin Grado Biotecnología
Entity: INSTITUTO DE BIOMEDICINA DE SEVILLA Type of entity: State agency
Number of recognized hours/ECTS credits: 120
Number of tutored students: 1
Educational or pedagogical publications, books, articles, etc.
1 Participation and promoter of GEIS and SEOM guidelines of GIST, Soft-tissue sarcoma and bone sarcomas.
Name of the materials: Clinical Guidelines
2 Participation in all the clinical guidelines editions in sarcomas of the European Society of Medical Oncology
(ESMO). ESMO.
Name of the materials: Clinical Guidelines
Other activities/achievements not included above
1 Description of the activity: XIII International GEIS Symposium
Organising entity: Grupo Español de investigación en sarcoma
End date: 21/11/2015
2 Description of the activity: VII Curso Avanzado de Sarcoma para residentes
End date: 13/06/2015
3 Description of the activity: Partícipe en International task force of Chordoma and GIST
Healthcare experience
Other activities/achievements not included above
1 Other relevant activities: Coordinador del Comité Multidisciplinar de tumores músculo-esqueléticos (COTMES)
del Hospital Son Espases y Son Dureta
Entity where project took place: Hospital Son Espases y Son Dureta
End date: 2014
2 Other relevant activities: Obtención de Evaluación positiva por parte de la Agència de Qualitat Universitària de
les Illes Balears formulada por el Comité de Ciencias de la Salud
Entity where project took place: Agència de Qualitat Universitària de les Illes Balears
End date: 2011
880568224a509ac22d7ad18cde2e9f428
3 Other relevant activities: Conferenciante en foros académicos con unas 40-60 conferencias/año y advisories de
expertos en sarcomas.
4 Other relevant activities: Faculty member de sarcomas en ESMO (desde 2009)
5 Other relevant activities: Member of Board of directors in Connective Tissue Oncology Society (CTOS) y de la
Sociedad Española de Oncologia Médica (SEOM)
6 Other relevant activities: Miembro de las plataformas Euroewing, Euramos y Eurosarc
7 Other relevant activities: Sinergias con varios equipos de investigación, tanto nacionales como internacionales,
con reconocido prestigio en investigación clínica y traslacional en Sarcomas
8 Other relevant activities: Socio de: American Society of Clinical Oncology (ASCO)
Scientific and technological experience
Scientific or technological activities
R&D projects funded through competitive calls of public or private entities
1 Name of the project: Improving neoadjuvant therapy in high-risk sarcomas
Geographical area: European Union
Degree of contribution: Researcher
Entity where project took place: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
Name principal investigator (PI, Co-PI....): Robin Jones; Valerie Brunton; Javier Martin Broto
Funding entity or bodies:
Cancer Research UK
Fondazione AIRC Type of entity: Associations and Groups
Asociación Española Contra el Cáncer Type of entity: Associations and Groups
City funding entity: Valencia, Valencian Community, Spain
Type of participation: Team member
Start-End date: 2019 - 2023
Total amount: 559.250 €
2 Name of the project: Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a
European and Latin American multidisciplinary network (SELNET)
Degree of contribution: Coordinator of total project, network or consortium
Type of entity: State agency
980568224a509ac22d7ad18cde2e9f428
Entity where project took place: INSTITUTO DE
BIOMEDICINA DE SEVILLA
City of entity: Sevilla, Andalusia, Spain
Name principal investigator (PI, Co-PI....): Javier Martin Broto
Type of participation: Principal investigator
Start-End date: 2019 - 2023 Duration: 4 years
Total amount: 3.100.000 €
3 Name of the project: Agentes antiangiogenicos en Tumor Fibroso Solitario: nuevas ideas en el mecanismo
de acción
Entity where project took place: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
Name principal investigator (PI, Co-PI....): Javier Martin Broto
Type of participation: Principal investigator
Start-End date: 2019 - 2022
Total amount: 111.000 €
4 Name of the project: Phase I clinical trial of Olaratumab plus Trabectedin in advanced soft-tissue sarcoma
patients (OLATRASTS)
Entity where project took place: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
Name principal investigator (PI, Co-PI....): Javier Martin Broto
Start-End date: 2019 - 2020
Total amount: 75.000 €
5 Name of the project: Exploring vasculature-related targets in angiosarcoma: an open road to new clinical
trials
Entity where project took place: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
Name principal investigator (PI, Co-PI....): Javier Martin Broto
Start-End date: 2018 - 2020
Total amount: 27.000 €
6 Name of the project: New insights in the mechanisms of action of cisplatin in rhabdomyosarcomas: waking
up an old drug for a fresh purpose
Entity where project took place: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
Name principal investigator (PI, Co-PI....): Javier Martin Broto
Start-End date: 2018 - 2020
Total amount: 52.000 €
7 Name of the project: REGISTRI. Phase II, single arm, non-randomized and multicenter clinical
trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or
unresectableKIT/PDGFR Wild Type GIST
Name principal investigator (PI, Co-PI....): Javier Martín-Broto; Italian coordinator Dr Elena Fumagalli
Nº of researchers: 18
Start-End date: 2015 - 2020
Total amount: 351.030 €
8 Name of the project: Consortium – International Clinical Trials to Improve Survival from Ewing’s Sarcoma
Nº of researchers: 31
Funding entity or bodies:
1080568224a509ac22d7ad18cde2e9f428
SEPTIMO PROGRAMA MARCO DE LA UNION EUROPEA
Start-End date: 2013 - 2020
9 Name of the project: Exploración de factores pronósticos moleculares relacionados con genotipo e
inmunomodulación en GIST localizados. PI15/01254
Entity where project took place: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
City of entity: sevilla, Andalusia, Spain
Name principal investigator (PI, Co-PI....): JAVIER MARTIN BROTO
Nº of researchers: 12
Funding entity or bodies:
Instituto de Salud Carlos III .Subprograma de proyectos de investigacion en salud (AES 2015).
Start-End date: 01/12/2015 - 31/12/2018
Total amount: 62.315 €
10 Name of the project: A PHASE II OPEN-LABEL TRIAL OF PAZOPANIB ADMINISTERED AS A SINGLE
AGENT IN PATIENTS WITH UNRESECTABLE OR METATSTATIC SOLITARY FIBROUS TUMOR (SFT)
AND EXTRASKELETAL MYXOID CHONDROSARCOMA (EMC)
Entity where project took place: Complejo Hospitalario Virgen del Rocío-IBIS
Nº of researchers: 14
Funding entity or bodies:
GSK-GEIS
Start-End date: 2014 - 2018
Total amount: 570.000 €
11 Name of the project: International Randomised Controlled Trial for the Treatment of Newly Diagnosed
Ewing’s Sarcoma Family of Tumors
Entity where project took place: Complejo Type of entity: Healthcare Institutions
Hospitalario Virgen del Rocío
Nº of researchers: 17
Funding entity or bodies:
SEPTIMO PROGRAMA MARCO DE LA UNION EUROPEA
Start-End date: 2013 - 2018
Total amount: 238.000 €
12 Name of the project: Análisis exploratorio de factores moleculares de inmunomodulación y apoptosis en
sarcomas y su posible papel pronóstico.
Name principal investigator (PI, Co-PI....): Nadia Hindi Muñiz
Start-End date: 2015 - 2017
Total amount: 8.000 €
13 Name of the project: Phase I-II trial exploring the combination of trabectedin plus radiotherapy in soft tissue
sarcoma patients.
Entity where project took place: Complejo Hospitalario Virgen del Rocío-IBIS
Nº of researchers: 19
Funding entity or bodies:
Pharma Mar, S.A. Type of entity: Business
City funding entity: Colmenar Viejo, Community of Madrid, Spain
Start-End date: 2014 - 2017
1180568224a509ac22d7ad18cde2e9f428
Total amount: 623.410 €
14 Name of the project: EUROSARC - EUROPEAN CLINICAL TRIALS IN RARE SARCOMAS WITHIN AN
INTEGRATED TRANSLATIONAL TRIAL NETWORK
Name principal investigator (PI, Co-PI....): JEAN YVES BLAY
Nº of researchers: 17
Funding entity or bodies:
SÉPTIMO PROGRAMA MARCO DE LA UE
Start-End date: 2011 - 2016 Duration: 5 years
Participating entity/entities: 9 M EUROS; ACADEMISCH ZIEKENHUIS LEIDEN; AZIENDA UNITA
SANITARIA N9 TREVISIO; EORTC; FONDAZIONE IRCCS; INSTITUT BERGONIE; INSTITUT GUSTAVE
ROUSSY; ISTITUTO ORTOPEDICO RIZZOLI; LYON INGENIERIE PROJETS. IMPORTE: 5; MARIA
SKLODOWSKA MEMORIAL CANCER CENTER; OXFORD GENE TECH; SPAEN; Servei de Salut de
les Illes Balears; UNIV. DE SALAMANCA; UNIV. OF BIRMINGHAM; UNIVERSITAET HEIDELBERG;
UNIVERSITE LYON 1 CL. BERNARD; UNIVERSITY OF OXFORD
15 Name of the project: Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared
de tronco en adultos: un enfoque integrador que incluye quimioterapia estándar vs histotipo-dirigida
neoadyuvante
Nº of researchers: 18
Funding entity or bodies:
SEPTIMO PROGRAMA MARCO DE LA UNION EUROPEA
Start-End date: 2011 - 2016
Total amount: 102.000 €
16 Name of the project: EC10-150 ENSAYO FASE I/II MULTICÉNTRICO Y PROSPECTIVO DE NILOTINIB Y
ADRIAMICINA COMO TRATAMIENTO NEOADYUVANTE EN LIPOSARCOMAS Y LEIOMIOSARCOMA DE
RETROPERITONEO.
Name principal investigator (PI, Co-PI....): JAVIER MARTÍN
Nº of researchers: 20
Funding entity or bodies:
MINISTERIO DE SANIDAD
Start-End date: 15/03/2011 - 30/06/2015 Duration: 2 years
Participating entity/entities: COMPLEJO HOSPITALARIO DE NAVARRA; HOSPITAL LA PAZ
DE MADRID; HOSPITAL MARQUÉS DE VALDECILLA; HOSPITAL SON ESPASES; HOSPITAL
VALL D’HEBRON; HOSPITAL VIRGEN DEL ROCÍO; Hospital Universitario de Canarias; INSTITUTO
VALENCIANO DE ONCOLOGÍA; MIGUEL SERVET; PUERTA DE HIERRO; XERAL CIES DE VIGO.
IMPORTE: 400.000 EUROS
Total amount: 400.000 €
17 Name of the project: Sarcomas de alto riesgo, de partes blandas, de extremidades y de Tronco superficial,
en estadio localizado: abordaje integrado Incluyendo quimioterapia adyuvante de tres o cinco ciclos. Estudio
prospectivo controlado randomizado fase III. Estudio colaborativo con el Grupo italiano de Sarcomas (ISG)
Nº of researchers: 18
Funding entity or bodies:
ISG
Start-End date: 2011 - 2015
Total amount: 70.000 €
1280568224a509ac22d7ad18cde2e9f428
18 Name of the project: Análisis mutacional de tumores de estroma gastrointestinal c-kit negativos o
débilmente positivos. correlación clínica y patológica
Nº of researchers: 1
Funding entity or bodies:
Novartis Farmacéutica, S.A. - GRUPO GEIS
Start-End date: 2007 - 2008
Total amount: 18.000 €
19 Name of the project: Proyecto iNTER Platform (International Network of Teleconsultation Excellence &
Referral)
Nº of researchers: 1
Funding entity or bodies:
CONSELLERIA D´ECONOMIA, HISENDA I INNOVACIO- DIRECCION GENERAL DE RECERCA,
DESENVOLUPAMENT TECNOLÓGIC I INNOVACION (GOVERN DE LES ILLES BALEARS)
Start-End date: 2007 - 2008
Total amount: 12.000 €
20 Name of the project: Ensayo fase II multicéntrico de palbociclib en segunda línea de sarcomas avanzados
con sobreexpresión CDK4.
Entity where project took place: Hospital Universitario Virgen del Rocío
City of entity: Sevilla, Andalusia, Spain
Name principal investigator (PI, Co-PI....): Javier Martín Broto
Start date: 2017
Total amount: 150.000 €
21 Name of the project: Immunomodulatory role of Pazopanib in Soft-tissue Sarcoma
Entity where project took place: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
City of entity: Sevilla, Andalusia, Spain
Name principal investigator (PI, Co-PI....): Javier Martín Broto
Start date: 2017
Total amount: 48.876,05 €
22 Name of the project: Phase I-II Trial of sunitinib plus nivolumab after standard treatment in advanced soft
tissue and bone sarcomas.
Entity where project took place: Hospital Universitario Virgen del Rocío
City of entity: Sevilla, Andalusia, Spain
Name principal investigator (PI, Co-PI....): Javier Martín Broto
Start date: 2017
Total amount: 80.000 €
23 Name of the project: Phase II Trial of nab-paclitaxel for the treatment of desmoid tumors and multiply
relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma.
Entity where project took place: Hospital Universitario Virgen del Rocío
City of entity: Sevilla, Andalusia, Spain
Start date: 2017
Total amount: 75.000 €
24 Name of the project: Targeting the tumour microenvironment in liposarcoma with Eribulin as backbone
Entity where project took place: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
1380568224a509ac22d7ad18cde2e9f428
Name principal investigator (PI, Co-PI....): Javier Martín Broto
Nº of researchers: 6
Funding entity or bodies:
Eisai.co., Ltd. Type of entity: Business
Start date: 2017
Total amount: 48.000 €
25 Name of the project: Targeting tumour microenvironment in sarcoma
Entity where project took place: INSTITUTO DE Type of entity: State agency
BIOMEDICINA DE SEVILLA
City of entity: Sevilla,
Name principal investigator (PI, Co-PI....): Javier Martín Broto
Nº of researchers: 6
Funding entity or bodies:
Pharma Mar, S.A. Type of entity: Business
City funding entity: Colmenar Viejo, Community of Madrid, Spain
Start date: 2017
Total amount: 41.628,64 €
26 Name of the project: REGISTRO DE SARCOMAS RAROS:HERRAMIENTA DE AYUDA PARA EVALUAR
EL NUMERO DE CASOS DE CADA SUBTIPO Y SU ORIENTACION TERAPEUTICA POR EL GRUPO
ESPAÑOL DE INVESTIGACION EN SARCOMAS (GEIS). "sUBESTUDIO Nº 2: BUSQUEDA DE
MOLECULAS DIANA RELEVANTES EN TUMORES DESMOIDES)
Name principal investigator (PI, Co-PI....): Rosa Alvarez; JM Trufero; Javier Martin Broto
Start date: 2016
27 Name of the project: ESTUDIO OBSERVACIONAL, RETROSPECTIVO Y MULTICÉNTRICO PARA
IDENTIFICAR LOS PERFILES DE PACIENTES QUE MÁS SE BENEFICIAN DEL TRATAMIENTO CON
TRABECTEDINA EN SEGUNDA LÍNEA EN PACIENTES CON SARCOMA DE TEJIDOS BLANDOS,
LOCALMENTE AVANZADOS O METASTÁTICOS, QUE HAN PROGRESADO A UN TRATAMIENTO DE
PRIMERA LÍNEA.” GEIS 38
Name principal investigator (PI, Co-PI....): JAVIER MARTIN BROTO; JAVIER MARTINEZ TRUFERO
Start date: 2015
28 Name of the project: EC11-444 ENSAYO FASE II MULTICÉNTRICO Y PROSPECTIVO CON
GEMCITABINA Y RAPAMICINA EN SEGUNDA LÍNEA DE OSTEOSARCOMA METASTÁSICO.
Name principal investigator (PI, Co-PI....): JAVIER MARTÍN
Nº of researchers: 15
Funding entity or bodies:
MINISTERIO DE SANIDAD
Start date: 15/03/2012 Duration: 2 years
Participating entity/entities: HOSPITAL DE LA SANTA CREU I SANT PAU; HOSPITAL INFANTIL
UNIVERSITARIO NIÑO JESÚS IMPORTE: 350.000 EUROS EUROS; HOSPITAL UNIVERSITARI
SON ESPASES; HOSPITAL UNIVERSITARI VALL D’HEBRON INSTITUT CATALÀ D’ONCOLOGIA
HOSPITALET; HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS HOSPITAL UNIVERSITARI I
POLITÈCNIC LA FE DE VALENCIA; HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA;
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO; HOSPITAL XERAL CIES; Hospital Sant Joan de Déu;
Hospital Universitario La Paz; Hospital Universitario Miguel Servet; Hospital Universitario Ramón y Cajal;
Hospital Universitario de Canarias
Total amount: 350.000 €
1480568224a509ac22d7ad18cde2e9f428
29 Name of the project: TRA-050 ESTUDIO TRASLACIONAL ASOCIADO AL ENSAYO FASE II
ALEATORIZADO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO DE DOXORRUBICINA VS
TRABECTEDINA EN PRIMERA LÍNEA DE PACIENTES CON SARCOMAS DE PARTES BLANDAS
AVANZADOS O METASTÁSICOS.
Name principal investigator (PI, Co-PI....): JAVIER MARTÍN
Nº of researchers: 2
Funding entity or bodies:
MINISTERIO DE SANIDAD
Start date: 01/01/2010 Duration: 1 year - 11 months - 30 days
Participating entity/entities: HOSPITAL SON ESPASES E INSTITUTO VALENCIANO DE ONCOLOGÍA
IMPORTE: 58.000 EUROS
Total amount: 58.000 €
30 Name of the project: ISA: INTER SUPPORT ACTION (INTERNATIONAL NETWORK OF
TELECONSULTATION EXCELLENCE & REFERRAL)
Name principal investigator (PI, Co-PI....): JAVIER MARTÍN
Nº of researchers: 10
Funding entity or bodies:
SÉPTIMO PROGRAMA MARCO DE LA UE
Start date: 01/09/2009 Duration: 2 years - 5 months - 27 days
Participating entity/entities: C2C CONSULTORÍA. IMPORTE: 779.895 EUROS; CMF HEALTH
MINISTRIES; DESARROLLO 2000 EN ÁFRICA; HOSPITAL DOCENTE DE TRUJILLO; HOSPITAL
SON ESPASES; HOSPITAL VALL D’HEBRON; Hospital Sant Joan de Déu; INSTITUTO NACIONAL DE
CANCEROLOGÍA DE MÉXICO; INSTITUTO VALENCIANO DE ONCOLOGÍA; UNIVERSIDAD DE NAIROBI
Total amount: 779,9 €
31 Name of the project: Estudio de la combinación de inhibidores tirosina quinasas con quimioterapia en
líneas celulares de sarcoma y GIST. Foco en el cronograma de administración para favorecer el efecto
sinergístico
Nº of researchers: 7
Funding entity or bodies:
GEIS (3ª Beca José Mª Buesa del Grupo GEIS de Ayuda a la Investigación en Sarcomas)
Total amount: 6.000 €
32 Name of the project: Tumores del estroma gastrointestinal (GIST) localizados, de riesgo intermedio y
alto, y completamente extirpados que expresan el receptor KIT: estudio aleatorizado controlado sobre el
tratamiento adyuvante con mesilato de imatinib (Glivec) en comparación con la administración de ningún
tratamiento después de la cirugía completa. Estudio colaborativo con la EORTC (European Organisation for
Research and Treatment of Cancer).
Name principal investigator (PI, Co-PI....): ANTONIO CASADO; ANDRES POVEDA
Nº of researchers: 18
Funding entity or bodies:
European Organisation for Research and Treatment Type of entity: 1
of Cancer
City funding entity: Valencia, Valencian Community, Spain
Total amount: 60.000 €
1580568224a509ac22d7ad18cde2e9f428
R&D non-competitive contracts, agreements or projects with public or private entities
1 Name of the project: International Randomised Controlled Trial of Chemotherapy for the treatment of
recurrent and primary refractory Ewing sarcoma
Degree of contribution: Researcher
Funding entity or bodies:
SEPTIMO PROGRAMA MARCO DE LA UNION EUROPEA (FP7)
Start date: 2014 Duration: 5 years
Total amount: 238.000 €
2 Name of the project: Estudio del potencial antitumoral de un nuevo fármaco diana en sarcomas.
Nº of researchers: 3
Funding entity or bodies:
HOSPITAL UNIVERSITARIO SON ESPASES
Start date: 2012 Duration: 1 year
Total amount: 3.000 €
3 Name of the project: Análisis exhaustivo de GISTs wild type para hallar nuevas dianas terapéuticas
Nº of researchers: 5
Funding entity or bodies:
HOSPITAL UNIVERSITARIO SON ESPASES
Start date: 2011 Duration: 2 years
Total amount: 14.000 €
Scientific and technological activities
Scientific production
Publications, scientific and technical documents
1 Javier Martin Broto; J Cruz; N Penel; A Le Cesne; N Hindi; P Luna; DS Moura; D Bernabeu; E De Alava; JA Lopez
Guerrero; J Dopazo; M Peña Chilet; A Gutierrez; P Collini; M Karanian; A Redondo; A Lopez Pousa; G Grignani; J
Diaz Martin; D Marcilla; A Fernandez Serra; C Gonzalez Aguilera; PG Casali; JY Blay; S Stacchiotti. Pazopanib for
treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncology. 21 - 3, pp.
456 - 466. 03/2020. ISSN 1470-2045
DOI: 10.1016/S1470-2045(19)30826-5
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 25 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 35.386 Journal in the top 25%: Yes
Source of citations: JCR Citations: 48,82
Relevant publication: Yes
1680568224a509ac22d7ad18cde2e9f428
2 Javier Martin Broto. Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children. The Lancet
Oncology. 21 - 1, pp. 16 - 17. 01/2020. ISSN 1470-2045
DOI: 10.1016/S1470-2045(19)30679-5
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 1 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 35.386 Journal in the top 25%: Yes
Position of publication: 59,1
Source of citations: JCR Citations: 48,82
Relevant publication: Yes
3 S Stacchiotti; S Ferrari; A Redondo; N Hindi; E Palmerini; MA Vaz Salgado; AM Frezza; PG Casali; A Gutierrez;
A Lopez Pousa; G Grignani; A Italiano; A LeCesne; S Dumont; JY Blay; N Penel; D Bernabeu; E De Alava; M
Karanian; C Morosi; S Brich; GP Dagrada; V Vallacchi; C Castelli; M Brenca; D Racanelli; R Maestro; P Collini; J
Cruz; J Martin Broto. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre,
single-arm, phase 2 trial. Lancet Oncology. 20 - 9, pp. 1252 - 1262. 09/2019. ISSN 1470-2045
DOI: 10.1016/S1470-2045(19)30319-5
Type of production: Scientific paper Format: Journal
Position of signature: 30
Total no. authors: 30 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 35.386 Journal in the top 25%: Yes
Source of citations: JCR Citations: 48,82
Relevant publication: Yes
4 WD Tap; H Gelderblom; E Palmerini; J Desai; S Bauer; JY Blay; T Alcindor; K Ganjoo; J Martin Broto; CW Ryan;
DM Thomas; C Peterfy; JH Healey; M Van de Sande; HL Gelhorn; DE Shurter; Q Wang; A Yver; HH Hsu; PS
Lin; S Tong-Starksen; S Stacchiotti; AJ Wagner. Pexidartinib versus placebo for advanced tenosynovial giant cell
tumour (ENLIVEN): a raddomised phase 3 trial. Lancet. 394 - 40197, pp. 478 - 487. 08/2019. ISSN 0140-6736
DOI: 10.1016/S0140-6736(19)30764-0
Type of production: Scientific paper Format: Journal
Position of signature: 9
Total no. authors: 23 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 59.102 Journal in the top 25%: Yes
Source of citations: JCR Citations: 247,29
Relevant publication: Yes
5 Javier Martin Broto; David S Moura; Nadia Hindi. Pazopanib in the treatment of advanced solitary fibrous
tumour-Autors'reply. Lancet Oncology. 20 - 3, pp. e128. 03/2019. ISSN 1470-2045
DOI: 10.1016/S1470-2045(19)30080-4
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 3 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 35.386 Journal in the top 25%: Yes
Source of citations: JCR Citations: 48.822
1780568224a509ac22d7ad18cde2e9f428
Relevant publication: Yes
6 Javier Martin Broto; Silvia Stacchiotti; Antonio Lopez Pousa; Andres Redondo; Daniel Bernabeu; Enrique De
Alava; Paolo G Casali; Antonine Italiano; Antonio Gutierrez; David S Moura; Maria Peña Chilet; Juan Diaz Martin;
Michele Biscuola; Miguel Taron; Paola Collini; Dominique Ranchere Vince; Xavier Garcia Del Muro; Giovanni
Griganani; Josefina Cruz. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous
tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncology. 20 - 1, pp. 134 - 144. 01/2019. ISSN 1470-2045
DOI: 10.1016/S1470-2045(18)30676-4
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 19 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 35.386 Journal in the top 25%: Yes
Source of citations: JCR Citations: 48,82
Relevant publication: Yes
7 David S Moura; Rafael Ramos; Antonio Fernandez Serra; Teresa Serrano; Julia Cruz; Ramiro Alvarez Alegret;
Rosa Ortiz Duran; Luis Vicioso; Maria Luisa Gomez Dorronsoro; Xavier Garcia Del Muro; Javier Martinez Trufero;
Jordi Rubio Casadevall; Isabel Sevilla; Nuria Lainez; Antonio Gutierrez; Cesar Serrano; Maria Lopez Alvarez;
Nadia Hindi; Miguel Taron; Jose Antonio Lopez Guerrero; Javier Martin Broto. Gene expression analyses
determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. Oncotarget. 3 - 9, pp. 17576 -
17588. 04/2018. ISSN 1949-2553
DOI: 10.18632/oncotarget.24799
Type of production: Scientific paper Format: Journal
Position of signature: 21
Total no. authors: 21 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 5.168 Journal in the top 25%: Yes
Source of citations: JCR Citations: 30,24
Relevant publication: Yes
8 S Stacchiotti; A Gronchi; P Fossati; T Akiyama; C Alapetite; M Baumann; J Y Blay; S Bolle; S Boriani; P Bruzzi;
R Capanna; A Caraceni; R Casadei; V Colia; J Debus; T Delaney; A Desai; P Dileo; S Dijkstra; F Doglietto; A
Flanagan; S Froelich; P A Gardner; H Gelderblom; Z L Gokaslan; R Haas; C Heery; N Hindi; P Hohenberger;
F Hornicek; R Imai; L Jeys; R L Jones; B Kasper; A Kawai; M Krengli; A Leithner; I Logowska; J Martin Broto;
D Mazzatenta; C Morosi; P Nicolai; O J Norum; S Patel; N Penel; P Picci; S Pilotti; S Radaelli; F Ricchini; P
Rutkowski; S Scheipl; C Sen; E Tamborini; K A Thornton; B Timmermann; V Torri; P U Tunn; M Uhl; Y Yamada;
D C Weber; D Vanel; P P Varga; C LA Vleggeert Lankamp; P G Casali; J Sommer. Best practices for the
Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus
Group.Annals of oncology. 28 - 6, pp. 1230 - 1242. 06/2017. ISSN 0923-7534
Type of production: Scientific paper Format: Journal
Position of signature: 39
Total no. authors: 65 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 13.930 Journal in the top 25%: Yes
Source of citations: JCR Citations: 38,74
Relevant publication: Yes
1880568224a509ac22d7ad18cde2e9f428
9 Alessandro Gronchi; Stefano Ferrari; Vittorio Quaqliuolo; Javier Martin Broto; Antonio Lopez Pousa; Giovanni
Griganani; Umberto Basso; Jean Yves Blay; Oscar Tendero; Robert Diaz Beveridge; Virginia Ferraresi; Iwona
Lugowska; Domenico Franco Merlo; Valeria Fontana; Emanuela Marchesi; Davide Maria Donati; Elena Palassini;
Emanuela Palmerini; Rita De Sanctis; Carlo Morosi; Silvia Stacchiotti; Silvia Bagué; Jean Michelle Coindre; Angelo
Paolo Dei Tos; Piero Picci; Paolo Bruzzi; Paolo Giovanni Casali. Histotype-tailored neoadjuvant chemotherapy
versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international,
open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncology. 18 - 6, pp. 812 - 822. 06/2017.
ISSN 1470-2045
DOI: 10.1016/S1470-2045(17)30334-0
Type of production: Scientific paper Format: Journal
Position of signature: 4
Total no. authors: 27 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 35.386 Journal in the top 25%: Yes
Source of citations: JCR Citations: 48,82
Relevant publication: Yes
10 Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With
Metastatic Soft-Tissue Sarcomas A Nonrandomized Phase 1/2 Clinical Trial. JAMA Oncology. 02/2020. ISSN
2374-2437
DOI: 10.1001/jamaoncol.2019.6584
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 30 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 21.886 Journal in the top 25%: Yes
Source of citations: JCR Citations: 22,42
11 Javier Martin Broto; Nadia Hindi; David Moura DS. Which goals should we purseue in each line of treatment for
advanced soft tissue sarcoma?. Future Oncology. 15 - 26s, pp. 17 - 23. 09/2019. ISSN 1479-6694
DOI: 10.2217/fon-2019-0490
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 3 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 2.279 Journal in the top 25%: No
Source of citations: JCR Citations: 4,05
12 G Fucà; Nadia Hindi; I Ray Coquard; V Colia; AP Dei Tos; Javier Martin Broto; M Brahmi; P Collini; D Lorusso;
F Raspagliesi; MA Pantaleo; B Vincenzi; E Fumagalli; A Gronchi; PG Casali; R Sanfilippo. Treatment outcomes
and sensitivity to hormone therapy of aggressive angiomyxoma: a multicenter, international, retrospective study.
Oncologist. 24 - 7, pp. e536 - e541. 07/2019. ISSN 1083-7159
DOI: 10.1634/theoncologist.2018-0338
Type of production: Scientific paper Format: Journal
Position of signature: 6
Total no. authors: 16 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 5.252 Journal in the top 25%: Yes
1980568224a509ac22d7ad18cde2e9f428
Source of citations: JCR Citations: 11,83
13 Javier Martin Broto; Nadia Hindi; J Cruz; J Martinez Trufero; C Valverde; LM De Sande; A Sala; L Bellido; A De
Juan; J Rubió Casadevall; R Diaz Beveridge; R Cubedo; O Tendero; D Salinas; I Gracia; R Ramos; S Baguè;
A Gutierrez; J Duran Moreno; A Lopez Pousa. Relevance of Reference Centers in Sarcoma Care and Quality
Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).
Oncologist. 24 - 6, pp. e338 - e346. 06/2019. ISSN 1083-7159
DOI: 10.1634/theoncologist.2018-0121
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 20 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 5.252 Journal in the top 25%: Yes
Source of citations: JCR Citations: 11.831
14 Alessandro Gronchi; Nadia Hindi; Josefina Cruz; Jean-Yves Blay; Antonio Lopez Pousa; Antoine Italiano; Rosa
Alvarez; Antonio Gutierrez; Inmaculada Rincon; Claudia Sangalli; Jose Luis Perez Aguiar; Jesus Romero;
Carlo Morosi; Marie Pierre Sunyach; Roberta Sanfilippo; Cleofe Romagosa; Dominique Ranchere Vince; Paolo
G. Casali; Javier Martin Broto. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of
a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.
EClinicalMedicine. 9 - 11, pp. 35 - 43. 03/2019. ISSN 2589-5370
DOI: 10.1016/j.eclinm.2019.03.007
Type of production: Scientific paper Format: Journal
Position of signature: 20
Total no. authors: 20 Corresponding author: No
15 Javier Martin Broto. Advancing towards Better Cooperation for Better Sarcoma Prognoses. Oncology. 95 - 1, pp. 5
- 10. 12/2018. ISSN 0030-2414
DOI: 10.1159/000494860
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 1 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 2.278 Journal in the top 25%: No
Source of citations: JCR Citations: 3,93
16 R Alemany; DS Moura; A Redondo; J Martinez Trufero; S Calabuig; C Saus; A Obrador Hevia; R Ramos; VH
Villar; C Valverde; MA Vaz; J Medina; I Felipe Abrio; Nadia Hindi; M Taron; Javier Martin Broto. Nilotinib as
Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for
Research on Sarcoma. Clinical Cancer Research. 24 - 21, pp. 5239 - 5249. 11/2018. ISSN 1078-0432
DOI: 10.1158/1078-0432.CCR-18-0851
Type of production: Scientific paper Format: Journal
Position of signature: 16
Total no. authors: 16 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 8.911 Journal in the top 25%: Yes
Source of citations: JCR Citations: 78,17
2080568224a509ac22d7ad18cde2e9f428
17 X Garcia Del Muro; J Maurel; J Martinez Trufero; J Lavernia; A Lopez Pousa; R De Las Peñas; R Cubedo; JP
Berros; A Casado Herráez; A De Juan; Javier Martin Broto. Phase II trial of ifosfamide in combination with the
VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS)
study. Investigational New Drugs. 36 - 3, pp. 468 - 475. 06/2018. ISSN 0167-6997
DOI: 10.1007/s10637-018-0583-z
Type of production: Scientific paper Format: Journal
Position of signature: 11
Total no. authors: 11 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 51.873 Journal in the top 25%: No
Source of citations: JCR Citations: 3,91
18 Options for treating different soft tissue sarcoma subtypes. Future Oncology. 14 - 10s, pp. 25 - 49. 05/2018. ISSN
1479-6694
DOI: 10.2217/fon-2018-0076
Type of production: Scientific paper Format: Journal
Position of signature: 4
Total no. authors: 5 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 2.279 Journal in the top 25%: No
Source of citations: JCR Citations: 4,05
19 S Pasquali; C Colombo; S Pizzamiglio; P Verderio; D Callegaro; S Stacchiotti; Javier Martin Broto; A Lopez Pousa;
S Ferrari; A Poveda; A De Paoli; V Quagliuolo; JC Jurado; A Comandone; G Grignani; R De Sanctis; E Palassini;
A Llomboart Bosch; AP Dei Tos; PG Casali; P Picci; A Gronchi. High-risk soft tissue sarcomas treated with
perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. European Journal of
Oncology. 93, pp. 29 - 36. 04/2018. ISSN 1128-6598
DOI: 10.1016/j.ejca.2018.01.071
Type of production: Scientific paper Format: Journal
Position of signature: 7
Total no. authors: 22 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 2.709 Journal in the top 25%: No
Source of citations: JCR Citations: 73
20 Juan Martin Liberal; Antonio Lopez Pousa; Javier Martinez Trufero; Javier Martin Broto; Ricardo Cubedo; Javier
Lavernia; Andrés Redondo; Jose Antonio Lopez Martín; Nuria Mulet Margalef; Xavier Sanjuan; Oscar M Tirado;
Xavier Garcia Del Muro. Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with
Advanced Soft-Tissue Sarcoma: a Spanish Group of Research on Sarcomas (GEIS) Study. Targeted Oncology. 13
- 1, pp. 81 - 87. 02/2018. ISSN 1776-2596
DOI: 10.1007/s11523-017-0539-9
Type of production: Scientific paper Format: Journal
Position of signature: 4
Total no. authors: 12 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 3.683
Source of citations: JCR Citations: 1,14
Relevant results: Q2
2180568224a509ac22d7ad18cde2e9f428
21 Stacchiotti, Silvia; Mir, Olivier; Le Cesne, Axel; Vincenzi, Bruno; Fedenko, Alexander; Maki, Robert G; Somaiah,
Neeta; Patel, Shreyaskumar; Brahmi, Mehedi; Blay, Jean Y; Boye, Kjetil; Sundby Hall, Kirsten; Gelderblom,
Hans; Hindi, Nadia; Martin-Broto, Javier; Kosela, Hanna; Rutkowski, Piotr; Italiano, Antoine; Duffaud, Florence;
Kobayashi, Eisuke; Casali, Paolo G; Provenzano, Salvatore; Kawai, Akira. Activity of Pazopanib and Trabectedin
in Advanced Alveolar Soft Part Sarcoma.The oncologist. 23 - 1, pp. 62 - 70. 01/2018. ISSN 1083-7159
DOI: 10.1634/theoncologist.2017-0161
Type of production: Scientific paper Format: Journal
Position of signature: 15
Total no. authors: 23
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 5.252 Journal in the top 25%: Yes
Source of citations: JCR Citations: 11,83
22 Martin-Broto, J; Redondo, A; Valverde, C; Vaz, M A; Mora, J; Garcia Del Muro, X; Gutierrez, A; Tous, C; Carnero,
A; Marcilla, D; Carranza, A; Sancho, P; Martinez-Trufero, J; Diaz-Beveridge, R; Cruz, J; Encinas, V; Taron,
M; Moura, D S; Luna, P; Hindi, N; Lopez-Pousa, A. Gemcitabine plus sirolimus for relapsed and progressing
osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for
Research on Sarcoma (GEIS).Annals of oncology. 28 - 12, pp. 2994 - 2999. 12/2017. ISSN 0923-7534
DOI: 10.1093/annonc/mdx536
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 21 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 96.304 Journal in the top 25%: Yes
Source of citations: JCR Citations: 40,75
23 Redondo, Andres; Bague, Silvia; Bernabeu, Daniel; Ortiz-Cruz, Eduardo; Valverde, Claudia; Alvarez, Rosa;
Martinez-Trufero, Javier; Lopez-Martin, Jose A.; Correa, Raquel; Cruz, Josefina; Lopez-Pousa, Antonio; Santos,
Aurelio; Garcia del Muro, Xavier; Martin-Broto, Javier. Malignant bone tumors (other than Ewing's): clinical practice
guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer
Chemotherapy and Pharmacology. 80 - 6, pp. 1113 - 1131. 12/2017. ISSN 0344-5704
DOI: 10.1007/s00280-017-3436-0
Type of production: Scientific paper Format: Journal
Position of signature: 14
Total no. authors: 14 Corresponding author: No
Impact source: JCR Category: Science Edition - PHARMACOLOGY &
PHARMACY
Impact index in year of publication: 62.360 Journal in the top 25%: No
Source of citations: JCR Citations: 9,61
24 Joensuu, Heikki; Blay, Jean-Yves; Comandone, Alessandro; Martin-Broto, Javier; Fumagalli, Elena; Grignani,
Giovanni; Del Muro, Xavier Garcia; Adenis, Antoine; Valverde, Claudia; Pousa, Antonio Lopez; Olivier, Bouche ';
Italiano, Antoine; Bauer, Sebastian; Barone, Carlo; Weiss, Claudia; Crippa, Stefania; Camozzi, Maura; Castellana,
Ramon; Le Cesne, Axel. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to
imatinib. British Journal Of Cancer. 117 - 9, pp. 1278 - 1285. 10/2017. ISSN 0007-0920
DOI: 10.1038/bjc.2017.290
Type of production: Scientific paper Format: Journal
Position of signature: 4
Total no. authors: 19
2280568224a509ac22d7ad18cde2e9f428
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 5.922 Journal in the top 25%: Yes
Source of citations: JCR Citations: 46,72
25 Jones, R. L.; Blay, J-Y.; Lecesne, A.; Martin-Broto, J.; Pontes, M. J.; Fernandez Santos, J. M.; Garcia San
Andres, B.; Wang, G.; Wang, S.; Shin, C. R.; Maki, R.; Patel, S.; Demetri, G. D. S.A matching-adjusted indirect
comparison of trabectedin and pazopanib for the treatment of advanced, metastatic, leiomyosarcomas. ANNALS
OF ONCOLOGY. 28, 09/2017. Available on-line at: . ISSN 0923-7534
Type of production: Scientific paper Format: Scientific and technical document or report
Source of citations: WOS Citations: 0
26 Hindi, N.; Fernandez-Serra, A.; Martinez-Trufero, J.; Carranza-Carranza, A.; Lopez-Pousa, A.; Lavernia, J.;
Arranz, J. L.; Alegret, R. Lopez; Martinez-Garcia, J.; Morales, C. Valverde; Cano, J. M.; Vaz, M. A.; Moura,
D. S.; Bague, S.; Gonzalez-Campora, R.; Lopez-Guerrero, J. A.; Martin-Broto, J.Analysis of expression
of immunomodulation factors in alveolar soft-part sarcoma: a retrospective study from the Spanish Group
for Research on Sarcoma (GEIS). ANNALS OF ONCOLOGY. 28, 09/2017. Available on-line at: . ISSN 0923-7534
Type of production: Scientific paper Format: Scientific and technical document or report
27 Serrano, C.; Lopez Pousa, A.; Pajares, I.; Valverde Morales, C.; Duran, J.; Rubio-Casadevall, J.; Safont, M. J.;
Martinez, V.; Diaz Beveridge, R.; Estival, A.; Vicente Baz, D.; Sebio Garcia, A.; Hindi, N.; Landolfi, S.; Olivares, D.;
Garcia-Valverde, A.; Ledesma, P.; Arribas, J.; Carles Galceran, J.; Martin Broto, J.Clinicopathologic features and
long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (> 5
years) to frontline imatinib (IM): A case-control study from GEIS. ANNALS OF ONCOLOGY. 28, 09/2017. Available
on-line at: . ISSN 0923-7534
Type of production: Scientific paper Format: Scientific and technical document or report
Source of citations: WOS Citations: 0
28 Mora, J.; Castaneda, A.; Perez-Jaume, S.; Lopez-Pousa, A.; Maradiegue, E.; Valverde, C.; Martin-Broto, J.; Garcia
del Muro, X.; Cruz, O.; Cruz, J.; Martinez-Trufero, J.; Maurel, J.; Vaz, M. A.; de Alava, E.; de Torres, C.GEIS-21:
a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of
Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). British Journal Of Cancer.
117 - 6, pp. 767 - 774. 09/2017. ISSN 0007-0920
DOI: 10.1038/bjc.2017.252
Type of production: Scientific paper Format: Journal
Position of signature: 7
Total no. authors: 15 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 5.416 Journal in the top 25%: Yes
Source of citations: JCR Citations: 45,89
29 Casali, P. G.; Le Cesne, A.; Poveda, A.; Kotasek, D.; Rutkowski, P.; Hohenberger, P.; Fumagalli, E.; Judson, I.;
Italiano, A.; Gelderblom, H.; Penel, N.; Kopp, H-G.; Goldstein, D.; Martin Broto, J.; Gronchi, A.; Wardelmann, E.;
Marreaud, S.; Zalcberg, J.; Litiere, S.; Blay, J-Y.Time to definitive failure to the first tyrosine kinase inhibitor in
localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC
STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial. ANNALS OF ONCOLOGY. 28, 09/2017.
ISSN 0923-7534
Type of production: Scientific paper Format: Scientific and technical document or report
2380568224a509ac22d7ad18cde2e9f428
30 Francisco Bautista; Soledad Gallego; Adela Cañete; Jaume Mora; Cristina Díaz de Heredia; Ofelia Cruz; José
María Fernández; Susana Rives; Pablo Berlanga; Raquel Hladun; Antonio Juan Ribelles; Luis Madero; Manuel
Ramírez; Rafael Fernández Delgado; Antonio Pérez Martínez; Cristina Mata; Anna Llort; Javier Martín Broto;
María Elena Cela; Gema Ramírez; Constantino Sábado; Tomás Acha; Itziar Astigarraga; Ana Sastre; Ascensión
Muñoz; Mercedes Guibelalde; Lucas Moreno. [Early clinical trials in paediatric oncology in Spain: a nationwide
perspective].Anales de pediatria. 87 - 3, pp. 155 - 163. (Spain): 09/2017. ISSN 1695-4033
DOI: 10.1016/j.anpedi.2016.07.007
Type of production: Scientific paper Format: Journal
Position of signature: 18
Total no. authors: 27
Impact source: JCR Category: Science Edition - PEDIATRICS
Impact index in year of publication: 1.318 Journal in the top 25%: No
Source of citations: JCR Citations: 1
31 Esther Martinez Font; Irene Felipe Abrio; Silvia Calabuig Fariñas; Rafael F Ramos; Josefa Terrasa; Oliver Vögler;
Regina Alemany; Javier Martín Broto; Antònia Obrador Hevia. Disruption of TCF/?-catenin binding impairs Wnt
signalling and induces apoptosis in soft tissue sarcoma cells.Molecular cancer therapeutics. 16 - 6, pp. 1166 -
1176. 06/2017. ISSN 1535-7163
DOI: 10.1158/1535-7163.MCT-16-0585
Type of production: Scientific paper Format: Journal
Position of signature: 8
Total no. authors: 9 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 4.856 Journal in the top 25%: Yes
Source of citations: JCR Citations: 18,06
32 Javier Martín Broto; Peter Reichardt; Silvia Stacchiotti; Jean-Yves Blay. Review of past and present clinical cases
with a view to future treatment options.Future oncology. 13 - 13s, pp. 11 - 28. 06/2017. ISSN 1479-6694
DOI: 10.2217/fon-2017-0120
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 4 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 2.369 Journal in the top 25%: No
Source of citations: JCR Citations: 3,83
33 Javier Martín Broto; Virginia Martinez Marin; César Serrano; Nadia Hindi; José Antonio López Guerrero; Rafael
Ramos Asensio; Ana Vallejo Benítez; David Marcilla Plaza; Ricardo González Cámpora. Gastrointestinal stromal
tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. Clinical and Translational
Oncology. 19 - 5, pp. 536 - 545. 05/2017. ISSN 1699-048X
DOI: 10.1007/s12094-016-1581-2
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 9 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 2.392 Journal in the top 25%: No
Source of citations: JCR Citations: 2,33
2480568224a509ac22d7ad18cde2e9f428
34 Andrés Poveda; Xavier García Del Muro; Jose Antonio López Guerrero; Ricardo Cubedo; Virginia Martínez;
Ignacio Romero; César Serrano; Claudia Valverde; Javier Martín Broto. GEIS guidelines for gastrointestinal
sarcomas (GIST).Cancer treatment reviews. 55, pp. 107 - 119. 04/2017. ISSN 1532-1967
DOI: 10.1016/j.ctrv.2016.11.011
Type of production: Scientific paper Format: Journal
Position of signature: 9
Total no. authors: 9 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 8.122 Journal in the top 25%: Yes
Source of citations: JCR Citations: 7.870
35 A. Gronchi; S. Stacchiotti; P. Verderio; S. Ferrari; J. Martin Broto; A. Lopez-Pousa; A. Llombart-Bosch; A.P. Dei
Tos; P. Collini; J. Cruz Jurado; A. De Paoli; D.M. Donati; A. Poveda; V. Quagliuolo; A. Comandone; G. Grignani;
C. Morosi; A. Messina; R. De Sanctis; S. Bottelli; E. Palassini; P.G. Casali; Piero Picci. Short, full-dose adjuvant
chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial
from the Italian Sarcoma Group and the Spanish Sarcoma Group. Annals of Oncology. 27 - 12, pp. 1 - 5. Oxford
University Press, 12/2016. ISSN 0923-7534
DOI: 10.1093/annonc/mdw430
Type of production: Scientific paper
Position of signature: 5
Total no. authors: 23 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 11.855 Journal in the top 25%: Yes
Source of citations: JCR Citations: 34,42
36 SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). Clinical and Translational Oncology. 18 -
12, pp. 1213 - 1220. 11/2016. ISSN 1699-048X
DOI: 10.1007/s12094-016-1574-1
Type of production: Scientific paper Format: Journal
Position of signature: 2
Total no. authors: 10 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 5.353
Source of citations: JCR Citations: 2,08
37 Marco Perez; Javier Peinado Serrano; Jose Manuel Garcia Heredia; Irene Felipe Abrio; Cristina Tous; Irene
Ferrer; Javier Martin Broto; Carmen Saez; Amancio Carnero. Efficacy of bortezomib in sarcomas with high levels
of MAP17 (PDZK1IP1).Oncotarget. 7 - 41, pp. 67033 - 67046. 10/2016. ISSN 1949-2553
DOI: 10.18632/oncotarget.11475
Type of production: Scientific paper Format: Journal
Position of signature: 7
Total no. authors: 9 Corresponding author: No
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 5.168 Journal in the top 25%: Yes
Source of citations: JCR Citations: 30,24
2580568224a509ac22d7ad18cde2e9f428
38 Javier Martin-Broto; Antonio López Pousa; Ramón De las Peñas; Xavier García del Muro; Antonio Gutierrez;
Javier Martinez-Trufero; Josefina Cruz; Rosa Alvarez; Ricardo Cubedo; Andrés Redondo; Joan Maurel; Juan
A Carrasco; José A López- Martin; Ángeles Sala; Andrés Meana; Rafael Ramos; Jordi Martinez-Serra; José
A Lopez-Guerrero; Isabel Sevilla; Carmen Balaña; Ángeles Vaz; Ana de Juan; Regina Alemany and Andrés
Poveda.Randomized Phase II Study Of Trabectedin And Doxorubicin Compared With Doxorubicin Alone As First
Line Treatment In Patients With Advanced Soft Tissue Sarcomas: A Spanish Group For Research On Sarcoma
(GEIS) Study. REVISTA: JCO (IN PRESS). Journal Clinical Oncology. 34 - 19, pp. 2294 - 2302. 07/2016.
Type of production: Scientific paper Format: Journal
Position of signature: 1
Total no. authors: 23 Corresponding author: Yes
Impact source: ISI Category: Oncology (nursing)
Impact index in year of publication: 18.443 Journal in the top 25%: Yes
39 J Martin-Broto; N. Hindi. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal
tumor.Current Opinion Oncology. 28 - 4, pp. 338 - 344. 07/2016. ISSN 1040-8746
DOI: 10.1097/CCO.0000000000000302
Type of production: Scientific paper
Position of signature: 1
Total no. authors: 2 Corresponding author: Yes
Impact source: JCR Category: Science Edition - ONCOLOGY
Impact index in year of publication: 3.414 Journal in the top 25%: No
Source of citations: JCR Citations: 2,96
Relevant results: Q2
40 J Maurel; A López-Pousa; S Calabuig; S Bagué; XG Del Muro; X Sanjuan; J Rubió-Casadevall; M Cuatrecasas;
J Martinez-Trufero; C Horndler; J Fra; C Valverde; A Redondo; A Poveda; I Sevilla; N Lainez; M Rubini; X
García-Albéniz; J Martín-Broto; E de Alava. Phosphorylated-insulin growth factor I receptor (p-IGF1R) and
metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19
study.Clinical Sarcoma Research. 29 - 6, 06/2016.
DOI: 10.1186/s13569-016-0050-6
Type of production: Scientific paper Format: Journal
Position of signature: 19
Total no. authors: 20 Corresponding author: No
Impact source: ISI
Impact index in year of publication: 2.11
41 VH Villar; O Vögler; F Barceló; J Martín-Broto; J Martínez-Serra; V Ruiz-Gutiérrez; R Alemany. Down-Regulation
of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue
Sarcoma.PLoS One. 24 - 11, 05/2016. ISSN 1932-6203
DOI: 10.1371/journal.pone.0155946
Type of production: Scientific paper Format: Journal
Position of signature: 4
Total no. authors: 7 Corresponding author: No
Impact source: JCR Category: Science Edition - MATERIALS SCIENCE,
MULTIDISCIPLINARY
Impact index in year of publication: 3.057 Journal in the top 25%: Yes
26You can also read
